28 research outputs found
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 9th edition
Dear Colleagues! We are glad to present the 9th Edition (revised) of Standards of Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation. The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), American Diabetes Association (ADA, 2018, 2019), American Association of Clinical Endocrinologists (AACE, 2019), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2014, 2018) and Russian Association of Endocrinologists (RAE, 2011, 2012, 2015). Current edition of the “Standards” also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals. Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 463 million patients by the end of 2019. According to the current estimation by the International Diabetes Federation, 578 million patients will be suffering from diabetes mellitus by by 2030 and 700 million by 2045. Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4 584 575 patients with DM in this country by the end of 2018 (3,1% of population) with 92% (4 238 503) – Type 2 DM, 6% (256 202) – Type 1 DM and 2% (89 870) – other types of DM, including 8 006 women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) con- firmed that only 54% of Type 2 DM are diagnosed. So real number of patients with DM in Russia is 9 million patients (about 6% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they don’t receive any treatment ant have high risk of vascular complications. Severe consequences of the global pandemics of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral, coronary and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death. In Ρurrent edition of the “Standards”: New goals of glycemic control for the elderly, based on the presence of functional dependence, as well as for pregnant women, children and adolescents, are given. Added a snippet that describes the continuous glucose monitoring. Only low-density lipoprotein cholesterol level is used as a target for lipid metabolism. Proposes more stringent target levels of blood pressure. It also features updated guidelines on stratification of treatment in newly diagnosed Type 2 diabetes: the excess of the initial level of HbA1c over the target level was used as a criterion. In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages. Recommendations for psychosocial support are added. The position of metabolic surgery as a method of treatment of DM with morbid obesity is updated. Recommendations for diagnostic and treatment of hypogonadism syndrome in men with DM are added. For the first time, evidence levels of confidence and credibility levels of recommendations for diagnostic, therapeutic, rehabilitative and preventive interventions based on a systematic review of the literature are given in accordance with the recommendations of the Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation. This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discus- sions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians and other medical professionals involved in the treatment of DM. On behalf of the Working Grou
Standards of specialized diabetes care. Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 10th edition
Dear Colleagues!We are glad to present the 10th Edition (revised) of the Standards of Specialized Diabetes Care. These evidence-based guidelines were designed to standardize and facilitate diabetes care in all regions of the Russian Federation.The Standards are updated on the regular basis to incorporate new data and relevant recommendations from national and international clinical societies, including World Health Organization Guidelines (WHO, 2011, 2013), International Diabetes Federation (IDF, 2011, 2012, 2013), European Association for the Study of Diabetes (EASD 2018, 2019), American Diabetes Association (ADA, 2018, 2019, 2021), American Association of Clinical Endocrinologists (AACE, 2020, 2021), International Society for Pediatric and Adolescent Diabetes (ISPAD, 2018) and Russian Association of Endocrinologists (RAE, 2019). Current edition of the βStandardsβ also integrates results of completed randomized clinical trials (ADVANCE, ACCORD, VADT, UKPDS, SAVOR, TECOS, LEADER, EXAMINE, ELIXA, SUSTAIN, DEVOTE, EMPA-REG OUTCOME, CANVAS, DECLARE, CARMELINA, REWIND, CREDENCE, CAROLINA, DAPA-CKD, DAPA-HF, EMPEROR-Reduced trial, VERIFY, VERTIS CV, PIONEER, etc.), as well as findings from the national studies of diabetes mellitus (DM), conducted in close partnership with a number of Russian hospitals.Latest data indicates that prevalence of DM in the world increased during the last decade more than two-fold, reaching some 537Β million patients by the end of 2021. According to the current estimation by the International Diabetes Federation, 643Β million patients will be suffering from DM by 2030Β and 784Β million by 2045.Like many other countries, Russian Federation experiences a sharp rise in the prevalence of DM. According to Russian Federal Diabetes Register, there are at least 4Β 871Β 863Β patients with DM in this country on 01.01.2021Β (3,34% of population) with 92,3% (4Β 498Β 826)βType 2Β DM, 5,6% (271Β 468)βType 1Β DM and 2,1% (101Β 569)βother types of DM, including 9Β 729Β women with gestational DM. However, these results underestimates real quantity of patients, because they consider only registered cases. Results of Russian epidemiological study (NATION) confirmed that only 54% of Type 2Β DM are diagnosed. So real number of patients with DM in Russia is 10Β million patients (about 7% of population). This is a great long-term problem, because a lot of patients are not diagnosed, so they donβt receive any treatment and have high risk of vascular complications.Severe consequences of the global pandemic of DM include its vascular complications: nephropathy, retinopathy, coronary, cerebral and peripheral vascular disease. These conditions are responsible for the majority of cases of diabetes-related disability and death.In Ρurrent edition of the βStandardsβ:New goals of glycemic control for continuous glucose monitoring (time in range, below range and above range, glucose variability) are given.It also features updated guidelines on stratification of treatment in newly diagnosed Type 2Β diabetes.In the recommendations for the personalization of the choice of antidiabetic agents, it is taken into account that in certain clinical situations (the presence of atherosclerotic cardiovascular diseases and their risk factors, chronic heart failure, chronic kidney disease, obesity, the risk of hypoglycemia) certain classes of hypoglycemic agents (or individual drugs) have proven advantages.Indications for the use of antidiabetic agents in chronic kidney disease are expanded.Information about insulin pump therapy is added.Recommendations on vaccination are added.An algorithm for replacing some insulin preparations with others is given.This text represents a consensus by the absolute majority of national experts, achieved through a number of fruitful discussions held at national meetings and forums. These guidelines are intended for endocrinologists, primary care physicians, pediatricians and other medical professionals involved in the treatment of DM.Compared with previous edition of the Standards of Specialized Diabetes Care edited by Dedov I.I., Shestakova M.V., ΒMayorov A.Yu., 10th edition, Moscow, 2021Β (signed for printing on 10.09.2021) a number of changes have been made.On behalf of the Working Grou
Diabetes mellitus type 2 in adults
Public organization “Russian Association of Endocrinologists”. Clinical guidelines. 
Diabetes mellitus type 1 in adults
Public organization “Russian Association of Endocrinologists”. Clinical guidlines
American Diabetes Association proposes to use HbA1c level for diagnosis of diabetes mellitus
ΠΠΌΠ΅ΡΠΈΠΊΠ°Π½ΡΠΊΠ°Ρ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠ°Ρ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ (ADA), Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ ΠΎΠ±Π½ΠΎΠ²Π»ΡΡΡΠ°Ρ ΡΠ²ΠΎΠΈ ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ, Π² ΠΈΡ
ΠΏΠ΅ΡΠ΅ΡΠΌΠΎΡΡΠ΅ 2010 Π³. Π±ΡΠ΄Π΅Ρ ΠΏΡΠ΅Π΄Π»Π°Π³Π°ΡΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΠ΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ. ΠΠ±Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π±ΡΠ΄ΡΡ ΠΊΠ°ΡΠ°ΡΡΡΡ ΠΌΠ½ΠΎΠ³ΠΈΡ
ΡΠ°Π·Π΄Π΅Π»ΠΎΠ², ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π·Π°ΡΡΠΎΠ½ΡΡ ΡΠ°Π·Π΄Π΅Π» Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ° ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ°?. ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΡΠ΅ΠΊΡΠΈΡ, ΡΠ°Π½Π΅Π΅ Π½Π°Π·ΡΠ²Π°Π²ΡΠ°ΡΡΡ ?ΠΡΠ΅Π΄ΠΈΠ°Π±Π΅Ρ?, Π±ΡΠ΄Π΅Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π° ΠΈ ΠΏΠ΅ΡΠ΅ΠΈΠΌΠ΅Π½ΠΎΠ²Π°Π½Π° Π² ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠΈΡΠΊΠ° Π΄ΠΈΠ°Π±Π΅ΡΠ°?
Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin
Intensification of antihyperglycaemic treatment in patients with poorly controlled type 2 diabetes mellitus who were on insulin therapy remains a difficult issue. Results from clinical trials with the sodium-glucose linked transporter (SGLT-2) inhibitor dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus using insulin are summarised and discussed in the article
Modern digital technologies in teaching philological disciplines
The purpose of writing an academic paper is to analyze a variety of digital technologies, the use of which is appropriate in the process of teaching philological disciplines and the determination of the basic factors that have a decisive influence on the quality of the modern educational process. The research methods: comparison, system-structural research, statistical-analytical method, tabular, graphical, analytical modeling, as well as methods of abstraction, analysis and generalization. As a result of the generalization of modern educational trends in various European countries, it has been determined that todayβs society is characterized by a high level of bilingualism and plurilingualism. The conducted study has proved that increasing level of digitalization of education is ensured through the application of effective regulatory measures by intergovernmental and national governments, as well as standardization, formalization, high quality educational services and integration of new digital technologies in teaching process
The 5th International Conference on Advanced Technologies Treatments for Diabetes (ATTD 2012),2012 February 8-11, Barcelona (Spain)
ΠΡΡΠ°Ρ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½Π°Ρ ΠΌΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΡ ATTD (Advanced Technologies & Treatment for Diabetes) ΠΏΡΠΎΡΠ»Π° 8?11 ΡΠ΅Π²ΡΠ°Π»Ρ 2012 Π³ΠΎΠ΄Π° Π² ΠΡΠΏΠ°Π½ΠΈΠΈ (Π³. ΠΠ°ΡΡΠ΅Π»ΠΎΠ½Π°). ΠΠ°Π½Π½ΠΎΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΠ΅ ΠΎΡΠ³Π°Π½ΠΈΠ·ΡΠ΅ΡΡΡ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ ΠΏΠΎΠ΄ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎΠΌ ΠΏΡΠΎΡ. Phillip Moshe (Institute for Endocrinology and Diabetes, Israel) ΠΈ Tadej Bottelino (University Children?s Hospital, Slovenia). Π 2012 Π³ΠΎΠ΄Ρ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠΈΠΉ ΡΠ΅Π·ΠΎΠ½Π°Π½Ρ Π² ΡΠ½Π΄ΠΎΠΊΡΠΈΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΌ ΡΠΎΠΎΠ±ΡΠ΅ΡΡΠ²Π΅ Π²ΡΠ·Π²Π°Π»ΠΈ ΠΈΠ½Π½ΠΎΠ²Π°ΡΠΈΠΈ Π² ΠΎΠ±Π»Π°ΡΡΠΈ ΠΏΠΎΠΌΠΏΠΎΠ²ΠΎΠΉ ΠΈΠ½ΡΡΠ»ΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π·Π°ΠΌΠΊΠ½ΡΡΠΎΠ³ΠΎ ΠΊΠΎΠ½ΡΡΡΠ°?, ΡΠ΅Π»Π΅ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΈ Π½Π΅ΠΏΡΠ΅ΡΡΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ½ΠΈΡΠΎΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³Π»ΠΈΠΊΠ΅ΠΌΠΈΠΈ. Π’ΡΠ°Π΄ΠΈΡΠΈΠΎΠ½Π½ΠΎ Π±ΡΠ» ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΡΠ΅ΡΠ΅Π΄Π½ΠΎΠΉ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠΉ Π²ΡΠΏΡΡΠΊ ?ATTD Yearbook 2011? ? ΠΊΠΎΠ»Π»Π΅ΠΊΡΠΈΡ ΡΠ΅ΠΏΡΠΈΠ½ΡΠΎΠ² Π»ΡΡΡΠΈΡ
ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Π½ΡΡ
Π·Π° Π³ΠΎΠ΄ ΡΡΠ°ΡΠ΅ΠΉ ΠΏΠΎ Π½ΠΎΠ²ΡΠΌ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠΌ Π² Π΄ΠΈΠ°Π±Π΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ Ρ ΠΊΠΎΠΌΠΌΠ΅Π½ΡΠ°ΡΠΈΡΠΌΠΈ ΡΠΊΡΠΏΠ΅ΡΡΠΎΠ²